Home - Asieris Pharmaceuticals

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

April 14, 2022

14 April 2022, Shanghai– Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021

View Details >

Now Hiring: Lab Manager (San Francisco)

March 28, 2022

Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major

View Details >

Now Hiring: Operations Manager (San Francisco)

March 27, 2022

Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major

View Details >

Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

March 26, 2022

Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major

View Details >

We strive for healthy and dignified lives.

News Releases

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

Now Hiring: Lab Manager (San Francisco)

Now Hiring: Operations Manager (San Francisco)

Now Hiring: Head of Toxicology, Director to Senior Director (Shanghai or San Francisco)

More info

Technology

Partner With Us

Links

News

Contact

Join Us